On July 16, 2025, MannKind Corporation (MNKD, Financial), a biopharmaceutical company, received a "Buy" rating from HC Wainwright & Co. The announcement comes from analyst Brandon Folkes, who provided the rating.
This rating includes a price target of $9.00 USD for MannKind (MNKD, Financial). This target suggests a favorable outlook for investors, aligning with the "Buy" recommendation, although there is no previous price target for comparison as a point of reference.
MannKind (MNKD, Financial) continues to be a focus of attention within the pharmaceutical sector, with market participants closely monitoring developments following this positive rating from HC Wainwright & Co.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for MannKind Corp (MNKD, Financial) is $9.43 with a high estimate of $12.00 and a low estimate of $7.00. The average target implies an upside of 144.90% from the current price of $3.85. More detailed estimate data can be found on the MannKind Corp (MNKD) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, MannKind Corp's (MNKD, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for MannKind Corp (MNKD, Financial) in one year is $8.04, suggesting a upside of 108.83% from the current price of $3.85. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the MannKind Corp (MNKD) Summary page.
